Tender detail
Open-house medicine discount agreements for rituximab
Summary
AOK Bayern intends to conclude non-exclusive discount agreements with pharmaceutical companies for medicines containing the active ingredient rituximab (ATC L01FA01). The agreements will start no earlier than 1 December 2026 and remain in force until 30 November 2028.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.